Search

everythinglearnresearchcommunity

for

Search:↓

Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Alopecia areata affects 1.45% of people in Japan, impacting mood and self-esteem, with many not seeking treatment.

Alopecia areata and atopic dermatitis have similar healthcare costs, but alopecia areata leads to more outpatient and long-term disability expenses.

Baricitinib is a safe and effective treatment for severe alopecia areata.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Patients need better information about the risks of long-term steroid use.

Plant-derived amino acids can help develop new antimicrobial drugs.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

People with alopecia areata face different healthcare access and experiences based on their race and ethnicity.

Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.

Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.

Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Removing myelin protein zero-like 3 in mice leads to better metabolism and resistance to obesity.

Some newly made compounds can block an enzyme linked to hair loss and prostate growth, with one in particular being very selective.

Negative expectations can cause adverse effects in dermatology treatments, like with finasteride for baldness, and careful communication can help reduce these nocebo responses.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.